{
    "clinical_study": {
        "@rank": "65436", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohorts 2/3", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This multicenter, open-label study will evaluate the maximum tolerated dose (MTD) and\n      dose-limiting toxicities of onartuzumab as single agent and in combination with sorafenib in\n      patients with advanced hepatocellular carcinoma. Patients in Cohort 1 will receive\n      onartuzumab as single agent on Day 1 of each 21-day cycle. Patients in Cohorts 2 and 3 will\n      receive onartuzumab on Day 1 of each 21-day cycle in combination with sorafenib 400 mg\n      orally daily or twice daily. Anticipated time on study treatment is until disease\n      progression or unacceptable toxicity occurs."
        }, 
        "brief_title": "A Study of Onartuzumab as Single Agent and in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Liver Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Liver Neoplasms", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/=  18 years of age\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          -  Cytologically or histologically confirmed diagnosis of hepatocellular carcinoma (HCC)\n\n          -  Advanced or metastatic disease\n\n          -  Child-Pugh class A liver function\n\n          -  Measurable disease as defined by RECIST 1.1\n\n        Exclusion Criteria:\n\n          -  Prior surgery or local therapy within 4 weeks prior to Cycle 1 Day 1, with the\n             exception of palliative radiation therapy to the bone\n\n          -  Brain metastasis or spinal cord compression not definitively treated with surgery\n             and/or radiation.\n\n          -  Granulocyte count < 1500/mm3, platelet count < 75,000/ mm3, and hemoglobin < 8 g/dL\n             within 7 days prior to Cycle 1 Day 1\n\n          -  Total bilirubin > 1.5 \u00d7ULN\n\n          -  AST (SGOT), ALT (SGPT), alkaline phosphatase (ALP) > 5 \u00d7ULN\n\n          -  Serum creatinine > 1.5 \u00d7 ULN or creatinine clearance < 60 cc/min by Cockcroft-Gault\n             formula\n\n          -  Significant history of cardiac disease within 6 months prior to Cycle 1 Day 1,\n             myocardial infarction within the previous year, or current cardiac ventricular\n             arrhythmias requiring medication\n\n          -  Serious active infection, or other serious underlying medical conditions that would\n             impair the ability of the patient to receive protocol treatment, with the exception\n             of HBV and HCV infections\n\n          -  Known active infection with human immunodeficiency virus (HIV) or known\n             HIV-seropositivity\n\n          -  Inability to take oral medication or untreated malabsorption syndrome\n\n          -  Pregnant or lactating women\n\n          -  History of transplantation including organ, bone marrow transplantation, and\n             peripheral blood stem cell transplantation with the exception of corneal\n             transplantation\n\n          -  Active bleeding diathesis (including active esophageal varices) within 8 weeks prior\n             to Cycle 1 Day1 that are not successfully treated\n\n          -  Uncontrolled hypertension\n\n          -  Treatment with any other investigational drug within 4 weeks of Cycle 1 Day 1"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01897038", 
            "org_study_id": "GO28651"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohorts 2/3"
                ], 
                "description": "Multiple doses", 
                "intervention_name": "onartuzumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohorts 2/3", 
                "description": "400 mg QD or BID", 
                "intervention_name": "sorafenib", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sorafenib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sarasota", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34232"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21231"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pokfulam", 
                        "country": "Hong Kong"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "169610"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "119228"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tainan", 
                        "country": "Taiwan", 
                        "zip": "00704"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "100"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Hong Kong", 
                "Singapore", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB GIVEN AS A SINGLE AGENT AND IN COMBINATION WITH SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: GO28651 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence and nature of dose-limiting toxicities (DLTs)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 42 days"
            }, 
            {
                "measure": "Incidence, nature and severity of adverse events, graded according to the NCI CTCAE v4.0", 
                "safety_issue": "No", 
                "time_frame": "up to approximately 31 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01897038"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }, 
            {
                "measure": "Steady-state plasma sorafenib concentrations when administered in combination with onartuzumab", 
                "safety_issue": "No", 
                "time_frame": "Day 1 Cycles 1-4"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "up to approximately 31 months"
            }, 
            {
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "up to approximately 31 months"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "up to approximately 31 months"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "up to approximately 31 months"
            }, 
            {
                "measure": "Progression-free survival at 4 months", 
                "safety_issue": "No", 
                "time_frame": "4 months"
            }, 
            {
                "measure": "Incidence of anti-therapeutic antibodies (ATAs) against onartuzumab", 
                "safety_issue": "No", 
                "time_frame": "up to approximately 31 months"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}